NasdaqGS:SVRABiotechs
Is Savara (SVRA) Fully Priced Following Its Recent Pullback?
Savara (SVRA) has drawn investor interest after recent share price moves, with the stock last closing at $5.41. The clinical stage biopharmaceutical company focuses on rare respiratory diseases, including autoimmune pulmonary alveolar proteinosis.
See our latest analysis for Savara.
Recent trading puts Savara’s 1 day share price return at 1.5%, while the 30 day share price return is down 13.0%. Even with this pullback, the 1 year total shareholder return of 100.4% and 5 year total shareholder...